MedTrace Logo

Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma

NCT00073736 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2011-08-12

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. MB07133 is being developed for the treatment of inoperable HCC, using a platform technology known as HepDirectTM, which enables drugs to be targeted specifically to the liver. The objective for this study is to determine the safety and tolerability of MB07133.

Conditions

Interventions

DRUG

MB07133 300mg/m2/day

7-day continuous infusion in 28-day cycles

DRUG

MB07133 600 mg/m2/day

7-day continuous infusion in 28-day cycles

DRUG

MB07133 1200 mg/m2/day

7-day continuous infusion in 28-day cycles

DRUG

MB07133 1800 mg/m2/day

7-day continuous infusion in 28-day cycles

DRUG

MB07133 2400 mg/m2/day

7-day continuous infusion in 28-day cycles

Sponsors & Collaborators

  • Ligand Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Isabela Niculae, MPH · Metabasis Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2007-07-31

Countries

  • United States
  • Hong Kong
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00073736 on ClinicalTrials.gov